Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-038600
Filing Date
2025-08-07
Accepted
2025-08-07 07:38:41
Documents
97
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20250630.htm   iXBRL 10-Q 2217687
2 EX-31.1 exhibit311-q22025.htm EX-31.1 10973
3 EX-31.2 exhibit312-q22025.htm EX-31.2 11033
4 EX-32.1 exhibit321-q22025.htm EX-32.1 7531
10 GRAPHIC akba-20250630_g1.gif GRAPHIC 3995
  Complete submission text file 0001628280-25-038600.txt   10453215

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20250630.xsd EX-101.SCH 87465
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20250630_cal.xml EX-101.CAL 84896
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20250630_def.xml EX-101.DEF 396654
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20250630_lab.xml EX-101.LAB 876100
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20250630_pre.xml EX-101.PRE 651399
100 EXTRACTED XBRL INSTANCE DOCUMENT akba-20250630_htm.xml XML 1381433
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 251191646
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)